Evidence map›Paper›PMID 37013071›Full record

ArticleCJC open2023

Apixaban in Patients With Post-Myocardial Infarction Left Ventricular Thrombus: A Randomized Clinical Trial.

Ali A Youssef, Mustafa A Alrefae, Hesham H Khalil, Hisham I Abdullah, Zizi S Khalifa, Amani A Al Shaban, Hammam A Wali, Mazen R AlRajab, Omar M Saleh, Baher N Nashy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CJC open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 6 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 6 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Pooled it
  5. Pooled it
  6. DOACs vs Warfarin for Post-myocardial Infarction Left Ventricular Thrombus: A GRADE-assessed Meta-Analysis With Trial Sequential Analysis of Randomized Trials.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  7. Review
  8. Observational
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ali A YoussefSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Mustafa A AlrefaeSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Hesham H KhalilSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Hisham I AbdullahSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Zizi S KhalifaDepartment of Cardiology, Zagazig University, Zagazig, Egypt.
Amani A Al ShabanSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Hammam A WaliSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Mazen R AlRajabSaud Albabtain Cardiac Centre, Dammam, Saudi Arabia.
Omar M SalehDepartment of Cardiology, Suez Canal University, Ismailia, Egypt.
Baher N NashyDepartment of Cardiology, Zagazig University, Zagazig, Egypt.
Suez Canal University · EGZagazig University · EGNational Heart Institute · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Direct oral anticoagulants are frequently used to treat post-myocardial infarction (MI) left ventricular thrombus (LVT). This study was conducted to evaluate the efficacy and safety of use of apixaban, compared to the standard warfarin therapy, in post-MI LVT. Methods: This open-label, randomized controlled trial included patients with post-acute or recent anterior wall MI with transthoracic echocardiography-confirmed LVT. Patients were randomized to receive either apixaban 5 mg twice daily or warfarin to achieve an international normalized ratio of 2-3, in addition to dual antiplatelet therapy. The primary endpoint was LVT resolution at 3 months, with a noninferiority margin of 95% for apixaban compared to warfarin. The secondary endpoint was major adverse cardiovascular events (MACE) or any relevant bleeding according to the Bleeding Academic Research Consortium (BARC) classification. Results: Fifty patients were enrolled from 3 centres. The use of dual or single antiplatelet agents was similar in the 2 groups. The number of 1-, 3-, and 6-month LVT resolutions were 10 (40.0%), 19 (76.0%), and 23 (92.0%) in the apixaban group, and 14 (56%), 20 (80.0%), and 24 (96.0%) in the warfarin group, respectively, without significant differences ( Conclusions: Apixaban was not inferior to warfarin in the resolution of post-MI LVT.

Identifiers

PMID37013071
PMCPMC10066447
OpenAlexW4311147792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.